O
DRUG

OrbiMed’s Bright Minds Biosciences DRUG Stock Holding History

OrbiMed’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.53M Buy
93,000
+53,000
+133% +$4.16M 0.12% 95
2026
Q1 		$2.92M Buy
+40,000
New +$3.22M 0.06% 104
2022
Q1 		– Sell
-132,120
Closed -$2.13M – 149
2021
Q4 		$2.13M Buy
+132,120
New +$2.94M 0.03% 149

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

OrbiMed's DRUG Position: Q2 2026 in Review

OrbiMed increased its Bright Minds Biosciences (DRUG) stake by 133% in Q2 2026, buying an estimated $4.16M and bringing the position to 93,000 shares worth $6.53M. The position accounts for 0.12% of the portfolio, ranked #95.

OrbiMed first reported a position in DRUG in Q4 2021 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • OrbiMed held 93,000 shares of Bright Minds Biosciences worth $6.53M as of Q2 2026.
  • OrbiMed bought 53,000 Bright Minds Biosciences shares in Q2 2026, an estimated $4.16M.
  • Bright Minds Biosciences made up 0.12% of OrbiMed's portfolio in Q2 2026, its #95 holding.
  • OrbiMed first reported a position in Bright Minds Biosciences in Q4 2021 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.